Document Detail


Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatment.
MedLine Citation:
PMID:  3123184     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Fourteen non-insulin-dependent diabetic (NIDDM) patients continued their previous medication (7 on glyburide, 7 on glipizide) for 6 mo, after which they switched to the alternate treatment for another 6 mo. The treatment periods were followed by 1 mo of placebo. The sulfonylurea dose was increased to achieve fasting plasma glucose levels less than 9 mM or to a total maximum daily dose of 25 mg. The mean final doses of glyburide (14.7 +/- 2.4 mg/day) and glipizide (15.2 +/- 2.2 mg/day) were similar. Postprandial (postdose) glipizide levels were higher than those of glyburide, whereas fasting (predose) glyburide concentrations were higher than those of glipizide. Both treatments improved glucose control by 25% compared with placebo. Glipizide therapy evoked higher postprandial insulin concentrations than did glyburide, whereas basal insulin concentrations were higher during glyburide. Insulin sensitivity, assessed by an insulin tolerance test, was more improved with glyburide than with glipizide. In conclusion, overall glucose control is similarly improved by glyburide and glipizide. However, glipizide amplifies the plasma insulin response to meals more than glyburide, whereas glyburide enhances basal insulin secretion more than glipizide. Both pharmacokinetic and pharmacodynamic factors may contribute to these differences.
Authors:
L Groop; P H Groop; S Stenman; C Saloranta; K J Tötterman; F Fyhrquist; A Melander
Related Documents :
15006824 - Optimal glycemic control in type 2 diabetes mellitus: fasting and postprandial glucose ...
517464 - Pericardial-fluid complement: normal values.
11574434 - Postchallenge hyperglycemia in a national sample of u.s. adults with type 2 diabetes.
22718504 - Evaluation of oxidative stress markers in pathogenesis of diabetic neuropathy.
3931804 - The southall diabetes survey: prevalence of known diabetes in asians and europeans.
2053214 - Gauging the likelihood of cavitation from short-pulse, low-duty cycle diagnostic ultras...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Diabetes care     Volume:  10     ISSN:  0149-5992     ISO Abbreviation:  Diabetes Care     Publication Date:    1987 Nov-Dec
Date Detail:
Created Date:  1988-03-16     Completed Date:  1988-03-16     Revised Date:  2010-08-11    
Medline Journal Info:
Nlm Unique ID:  7805975     Medline TA:  Diabetes Care     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  671-8     Citation Subset:  IM    
Affiliation:
Fourth Department of Medicine, Helsinki University Hospital, Finland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Blood Glucose / metabolism
C-Peptide / blood
Clinical Trials as Topic
Diabetes Mellitus, Type 2 / blood,  drug therapy*,  urine
Fasting
Female
Glipizide / pharmacokinetics*,  pharmacology,  therapeutic use
Glyburide / pharmacokinetics*,  pharmacology,  therapeutic use
Glycosuria
Hemoglobin A, Glycosylated / analysis
Humans
Insulin / blood
Lipids / blood
Male
Middle Aged
Sulfonylurea Compounds / pharmacokinetics*
Chemical
Reg. No./Substance:
0/Blood Glucose; 0/C-Peptide; 0/Hemoglobin A, Glycosylated; 0/Lipids; 0/Sulfonylurea Compounds; 10238-21-8/Glyburide; 11061-68-0/Insulin; 29094-61-9/Glipizide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Glyburide and glipizide in treatment of diabetic patients with secondary failures to tolazamide or c...
Next Document:  Factors related to discontinuation of continuous subcutaneous insulin-infusion therapy.